Writing the Application
Six pages is the whole case a Phase I application gets to show why the problem matters, what is new about the answer and how the experiments will prove it (NIH page limits). Phase II and Fast-Track applications get twelve. Every other section either feeds those pages or proves the company can carry the result to market, so write the Specific Aims first and build outward from them.
Project Summary and Narrative
The Project Summary becomes the public record of the award, since NIH RePORTER publishes the abstract of every funded project. It has 30 lines to state the problem, the product, the aims and the commercial use, written for a scientifically literate reader outside your field. The Project Narrative gets three sentences on relevance to public health. Write it in plain language for a general audience, and name both the patients who benefit and the health outcome you expect to change.
Specific Aims
One page holds the full argument for the project. Open with the clinical or market gap and the hypothesis that answers it, then list aims that each end in a measurable result. For Phase I, close each aim with the result that would justify a Phase II, stated as a number or a threshold. Avoid aims that depend on each other, because one failed experiment can then sink the whole project.
Research Strategy
Significance comes first, with the market need set beside the scientific one, because reviewers are asked whether a Phase I project could lead to a marketable product (PA-27-100). Innovation names the products or methods your solution competes with and the advantage it holds over each. Approach carries the preliminary data and the experimental design, along with expected results, benchmarks for success and an alternative for every aim that could fail. A Phase II Approach also has to report what the Phase I work achieved. Phase I applications cannot carry an appendix, so every figure and table that supports feasibility has to fit inside the six pages.
Commercialization Plan
A Phase I application may not include one, while every Phase II, Direct to Phase II and Fast-Track application must. NIH allows twelve pages, organized under the section headings its form sets out (NIH Form G.440).
- Value of the SBIR/STTR Project, Expected Outcomes, and Impact - the need, the Phase III product and how the project fits your business plan, in terms a lay reader can follow.
- Company - your origins, funding and regulatory history, current products and the management plan for growth.
- Market, Customer, and Competition - the target customer and the hurdles to adoption, with partners for FDA approval or sales and every competitor you know of.
- Intellectual Property Protection - how you'll protect what the project produces and hold off competitors once it ends.
- Finance Plan - how much money commercialization needs, by when, and where it will come from.
- Production and Marketing Plan - how the product will be made, and the steps you'll take to market and sell it.
- Revenue Stream - the revenue model, and how staffing changes if the project succeeds.
NIH doesn't require the full twelve pages.
Letters of Support
NIH encourages you to secure commitments of funds or resources from investors or partners who would help commercialize the product, and those letters belong in the application. Place them in the Letters of Support attachment, after the letters from consultants and collaborators. Ask each writer to state what they will provide and when, since a letter with a figure and a date can be checked against your Finance Plan.
Budget Justification
Every budget limit under PA-27-100 covers direct costs, indirect costs and fee combined. Reviewers weigh whether the budget and the requested period of support are fully justified for the work proposed, so tie each major cost to a named aim and month.